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Abstract
Background The serotonin 5-HT1A receptor (5-HT1AR) and metabotropic glutamate receptor 4 (mGlu4) have been impli-
cated as sites of antipsychotic drug action. 5-HT1AR belongs to the A class of G protein-coupled receptors (GPCRs); mGlu4 
is a representative of class C GPCRs. Both receptors preferentially couple with Gi protein to inhibit cAMP formation. The 
present work aimed to examine the possibility of mGlu4 and 5-HT1A receptor cross-talk, the phenomenon that could serve 
as a molecular basis of the interaction of these receptor ligands observed in behavioral studies.
Methods First, in vitro studies were performed to examine the pharmacological modulation of interaction of the mGlu4 and 
5-HT1A receptors in the T-REx 293 cell line using SNAP- or HALO–tag and cAMP accumulation assay. Next, the colocali-
zation of these two receptors was examined in some regions of the mouse brain by applying RNAScope dual fluorescence 
in situ hybridization, immunohistochemical labeling, and proximity ligation assay (PLA).
Results The ex vivo and in vitro results obtained in the present work suggest the existence of interactions between mGlu4 
and 5-HT1A receptors. The changes were observed in cAMP accumulation assay and were dependent on expression and 
activation of mGlu4R in T-REx 293cell line. Moreover, the existence of spots with proximity expression of both receptors 
were showed by PLA, immunofluorescence labeling and RNAscope methods.
Conclusion The existence of interactions between mGlu4 and 5-HT1A receptors may represent another signaling pathway 
involved in the development and treatment psychiatric disorders such as schizophrenia or depression.
Keywords Cell signaling · Gpcrs · Cross-talk · mGlu4 receptors · 5-HT1A receptors
Introduction
The G protein-coupled receptors (GPCRs) form the larg-
est and most diverse receptor superfamily in mammals [1]. 
The International Human Genome Sequencing Consortium 
reported a total of 569 rhodopsin-like GPCRs [2]. It has been 
estimated that approximately 34–50% of all modern drugs 
act on GPCRs [3].
Data suggesting the possibility of GPCR oligomer forma-
tion were reported for the first time in the 1970s; the forma-
tion of β-adrenergic receptor homodimers was described [4]. 
Then, in the early 1990s, Ferre and coworkers [5] demon-
strated GPCR heteromer formation between adenosine A2 
and dopamine D2 receptors in rat striatal membranes. Thus, 
it has been postulated that oligomerization might provide 
an additional level of signaling diversity and complicity 
provided by cross-talk between two different receptors. The 
interaction of receptors like cross-talk or oligomerization 
might induce functional and structural changes that lead 
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to new features of established protein complexes, affecting 
binding sites, modulating GPCR signaling and activating 
alternative signaling pathways.
In the present study, we examined the possibility of inter-
action of members of two different classes of GPCR. First, 
the metabotropic glutamate 4 receptor (mGlu4) is a repre-
sentative of class C GPCRs [6, 7]. It is a large protein of 
approximately 105 kDa assembled from 912 amino acids 
(aa). mGlu4 shares structural features common to mGlu 
receptors with large extracellular domains, seven transmem-
brane domains and a C-terminal tail. The extracellular part 
consists of a venous flytrap domain (VFT) with a binding 
site for orthosteric ligands and a cysteine-rich domain linked 
with 7TM. Like other members of group III mGlu recep-
tors, its activation inhibits the activity of adenylate cyclase 
(AC), thus decreasing cAMP concentration in cells [8]. In 
the central nervous system (CNS), the mGlu4 receptor is 
predominantly presynaptically expressed within the active 
zone of neurotransmitter release and controls synaptic firing. 
The highest expression of mGlu4 is observed in the cerebel-
lum as well as in the cerebral cortex and the hippocampus 
[9]. The preclinical data show that orthosteric agonists and 
positive allosteric modulators (PAMs) of mGlu4 receptors 
induce a dose-dependent reversal in the positive, negative 
and cognitive symptoms observed in an animal model of 
schizophrenia [10–12].
The 5-HT1A receptor belongs to the A class of GPCRs 
and consists of 421 aa in humans. Its N-terminus (extracel-
lular part) consists of no more than 30 aa. Similar to the 
mGlu4 receptor, the serotonin receptor 1A preferentially 
couples with Gi/o protein to inhibit cAMP formation [13]. 
In the brain, presynaptic and postsynaptic pools of 5-HT1A 
receptors exist. The presynaptic 5-HT1A receptors are 
located in the dorsal raphe and function as somatodendritic 
autoreceptors on serotoninergic nerve endings; the postsyn-
aptic receptors can be found in the CA1 area and the dentate 
gyrus of the hippocampus [14]. Moreover, the 5-HT1A recep-
tor activates phosphatidylinositol-specific phospholipase C 
and other phospholipases, activates several different protein 
kinases and regulates the function of several distinct types of 
ion channels [13]. The 5-HT1A receptor was considered for 
many years to be a target for the treatment of a number of 
CNS disorders, including depression [15] and schizophrenia.
[16].
Both receptors have been shown to interact with other 
GPCRs. For example, 5-HT1A can interact with serotonin 
5-HT7, dopamine D2 and μ-opioid receptors [17, 18].The 
interaction of mGlu4 receptor with other mGlu receptors 
from groups II and III (but not group I) [19] has been shown. 
To date, there is no information concerning the interac-
tion between 5-HT1A and mGlu4 receptors. However, the 
existing data suggest that the antipsychotic-like activity of 
mGlu4 orthosteric agonists and PAMs were dependent on 
serotonergic signaling via 5-HT1A receptors [20] because 
the effects of sub effective doses of mGlu4 agonists/PAMs 
in several behavioral tests were potentiated by sub effective 
doses of the selective 5-HT1A agonist (R)-(+)-8-hydroxy-
DPAT [21], while the antipsychotic-like activity of the 
effective doses of the mGlu4 compounds was blocked by 
the selective 5-HT1A receptor antagonist WAY100635 [22].
Therefore, the present work aimed to examine the pos-
sibility of mGlu4 and 5-HT1A receptors cross-talk—the 
phenomenon that could serve as a molecular basis of the 
interaction of these receptor ligands observed in behavioral 
studies. In vitro studies were performed to examine the phar-
macological modulation of the mGlu4 and 5-HT1A recep-
tor signaling in the T-REx 293 cell line. We evaluated the 
pharmacological response of mGlu4 and 5-HT1A receptors 
by measuring cAMP levels upon stimulation with receptor 
agonists, L-Glu, (R)-(+)-8-OH DPAT or both. Moreover, 
the cells could be considered as the endogenous source of 
the glutamate which can stimulate mGlu4R and influence 
the activity of the test system. Thus, the effect of an inhibi-
tor of the glutamate antiporter, the sulfasalazine (SSZ) was 
investigated. Additionally, potential molecular interaction 
was measured by a HTRF-FRET assay in the presence of 
L-Glu, (R)-(+)-8-OH DPAT. To examine whether the inter-
action between 5-HT1A and mGlu4 exists in the natural neu-
ral system, colocalization of the receptors was examined in 




A DNA fragment encoding variant 1 of human metabotropic 
glutamate receptor 4 (GRM4, NM_000841) was obtained 
from the University of Missouri, and the fragment encoding 
serotonin receptor 1a (5-HT1A) was obtained from Origene. 
The SNAP-tag and Halo-tag plasmids ware obtained from 
New England Biotech.
The GRM4 sequence was subcloned into the pcDNA5/
FRT/TO multi cloning site as described by Chruścicka et al. 
[23]. Then, after the 28th amino acid of the signaling peptide 
sequence containing the site for AgeI and SbfI, restriction 
enzymes was inserted using the QuikChange Lightning Site-
Directed Mutagenesis Kit (Aligent Stratagene) according to 
the manufacturer’s instructions. Two primers were used to 
introduce the restriction sites: CCT TCC TCC CTG GGA ACC 
GGT TTC CCT GCA GGA AAG CCC AAA GGCC and GGC 
CTT TGG GCT TTC CTG CA GGG AAA CCG GTT CCC AGG 
GAG GAA GG. Thereafter, sequencing (primer: AGG CTT 
GGT GAT GAT GGG TG) and restriction analysis was per-
formed to confirm the introduction of the new restriction 
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sites (Fig. S1). A fragment encoding the SNAP protein was 
subcloned from the pSNAP vector into a modified sequence 
of GRM4 by AgfI and SbfI enzymes. Insertion was con-
firmed by restriction analysis, immunostaining and func-
tional assay. 5-HT1A was subcloned from the pcDNA3.1 
plasmid into the pCLIP-Vector (BamHi and XhoI). Due to 
the lack of satisfactory substrate specificity between the 
SNAP-tag and CLIP-tag, the CLIP sequence was changed 
to the HALO-tag. The pHTN HALO-Tag CMV-neo vector 
(Promega) fragment containing the HALO sequence and 
part of the CMV promoter was exchanged with a similar 
sequence in the CLIP-5-HT1A plasmid (NdeI and SbfI).
The T-REx 293 cell line (Invitrogen) is recombinant 
HEK-293 cell line transfected with tetracycline-inducible 
gene expression system. The cell line was maintained in 
DMEM medium supplemented with 10% FBS (tetracycline 
free), 2 mM Glutamax I (Lonza,), 100 µg/mL Zeocin and 
10 µg/mL blasticidin (Invitrogen). T-REx 293 cells were 
treated with a mixture of plasmids (0.1 µg pTet-SNAP-
GRM4 and 0.9 µg pOG44) and GeneJuice transfection rea-
gent according to the manufacturer’s instructions (Novagen). 
After 48 h, selection for the stably integrated plasmid with 
100 µg/mL hygromycin B (Invitrogen) began. In parallel 
experiments, the HALO-5-HT1A plasmid was introduced 
into T-REx 293 cells or cells with the inducible expres-
sion of SNAP-GRM4 to generate a cell line that expressed 
both receptors. In the double expression system (as well as 
in other experiments), 5-HT1A was stably expressed, and 
mGlu4R expression was induced by tetracycline treatment 
(+ Tet; 0.75 µg/mL) (Fig. S3). One additional cell line was 
generated by cloning the 5-HT1A insert (BamHI/XhoI) into 
the pSNAPf vector (New England Biotechnologies).
Forskolin‑induced cAMP accumulation assay
The determination of intracellular cAMP using a homogene-
ous time-resolved fluorescence (HTRF) cAMP dynamic 2 
kit from Cisbio was performed according to our previously 
described methodology [23]. Briefly, cells were grown in 
DMEM medium with FBS and without tetracycline. Forty-
eight hours before experiments, mGlu4 receptor expression 
was induced by adding 0.75 µg/mL tetracycline. 24 h before 
the experiment, FBS was removed, cells were scraped and 
centrifuged. The cell pellet was suspended in Hanks-HEPES 
buffer (130 mM NaCl, 5.4 mM KCl, 1.8 mM  CaCl2, 0.8 mM 
 MgSO4, 0.9 mM  NaH2PO4, 20 mM HEPES, and 3.25 mM 
glucose; pH 7.4) and it was incubated in the presence of 
5 µM forskolin and the following agonists: l-glutamate; 
(R)-(+)-8-OH DPAT; WAY100635, a 5-HT1A receptor 
antagonist; and VU0155041, a positive modulator of mGlu4 
receptors. After 10 min incubation, 10 µL cell suspension 
was incubated with 5 µL cAMP-d2 conjugate and 5 µL anti-
cAMP cryptate conjugate. Following 1 h of incubation at 
room temperature), the fluorescence at 620 nm and 665 nm 
was determined (Tecan Infinite M1000). The results were 
calculated as the 665 nm/620 nm ratio multiplied by  104. 
Additionally, the effect of sulfasalazine, an inhibitor of the 
cystine-glutamate antiporter on cAMP level in T-REx 293 
expressing both receptors was examined. SSZ was present 
in culture medium without L-Glu from the time point of 
tetracycline addition and over cAMP assay in concentration 
100 µM.
In vitro receptor interaction assays
T-REx 293 cells expressing one or both labeled receptors 
were harvested from the cell culture flask, centrifuged and 
suspended in PBS at 2 × 106 cells/mL (without  Ca+2/Mg+2, 
with 3.25 mM glucose and 0.1% BSA). Thereafter, the 
cells were incubated with the following fluorescence sub-
strates for 2 h at 37 °C with slow agitation (90 rpm on an 
orbital shaker): 100 nM Snap-Tb (Cisbio), 150 nM Snap-
Green (Cisbio) and 200 nM Halo-Alexa 488 (Promega) then 
washed and centrifuged three times to remove unbound sub-
strates. In the final step, the cells were suspended in Hanks-
HEPES buffer and fluorescence signals were measured on 
a TECAN Infinity M1000 (white 384 low volume plate; 
20,000 cells per well in a total volume of 20 μL; Greiner 
BIO-ONE) in two channels: (1) donor Snap-Tb (ex. 320 nm; 
em. 490 nm; delay 50 μs, integration 700 μs) and (2) FRET 
signal (ex.320 nm; em. 520 nm; delay 50 μs, integration 
700 μs). The intermolecular interaction was presented as 
a ratio (FRET/Snap-Tb)  x10e4. Receptor interactions were 
analyzed in the presence of the mGlu4 receptor agonist 
l-glutamate; the 5-HT1A agonist (R)-(+)-8-OH DPAT [24]; 
the positive modulator of mGlu4 receptors VU0155041 [25]; 
and the 5-HT1A receptor antagonist WAY100635 [26].
Animals
Animal studies were carried out in accordance with the 
European Community guidelines and national law. The 
mouse C57BL/6J (the Jackson Laboratory) in the age of 
three mount had free access to food and water and were 
kept at constant room temperature (24 °C), under 12-h light/
dark cycle. After decapitation, mouse brains were removed, 
immediately frozen on dry ice and stored at − 80 °C until 
cryosectioning.
RNAscope in situ hybridization assay
The RNAscope in  situ hybridization (ISH) procedure 
described by Wang et al. was applied [27]. Coronal sections 
(thickness: 10 μm) were cut with a Cryostat (Leica Microsys-
tems GmbH, CM 3000) at −  20  °C and thaw-mounted 
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directly onto Super Frost Plus slides (Menzel). The slides 
were stored at − 20 °C until ISH processing.
RNAScope ISH for Htr1a and GRM4 mRNAs was man-
ually performed according to the User Manual for Fresh 
Frozen Tissue using the RNAscope Multiplex Fluorescent 
Reagent Kit (Advanced Cell Diagnostics Srl, Italy). The 
slides with brain sections were fixed in 4% paraformalde-
hyde in PBS. The target probes for specific mRNAs (Htr1a 
and GRM4) were applied to the brain sections and incu-
bated at 40 °C for 2 h in the EZ Hybridization Oven. These 
probes were as follows: GRM4-C1 probe (accession number 
(NM_001291045.1; target nucleotide region: 1076-2146); 
Htr1a-C2 probe (accession number NM_008308.4; target 
nucleotide region: 563–1824). Finally, the sections were 
incubated for 30  s with 4′,6-diamidino-2-phenylindole 
(DAPI) to stain nuclei (blue) and the slides were mounted 
with ProLong Gold Antifade Mountant (Thermo Fisher 
Scientific).
Fluorescent images were acquired using the Axio Imager 
2 fluorescence microscope equipped with excitation and 
emission filters compatible with the fluorophores used, 
20 × and 40 × objectives, and a camera (Carl Zeiss Micro-
Imaging GmbH, Germany).
Double immunofluorescence labeling
Brain coronal sections (thickness: 10 µm) were fixed in 4% 
paraformaldehyde in PBS for 10 min and rinsed in PBS (3 
times for 5 min each) incubated in blocking solution (5% 
normal donkey serum in PBS) for 30 min at RT, then over-
night at 4 °C with a mixture of primary antibodies. Final 
concentration of anti-5-HT1A receptor antibody (goat poly-
clonal, ab101914, Abcam) was 1:200, and of the anti-mGlu4 
receptor antibody (rabbit polyclonal, SAB4501322, Sigma 
Aldrich) it was 1:50. On the following day, the sections were 
incubated for 1 h at room temperature with secondary anti-
bodies: Alexa Fluor 488 donkey anti-rabbit IgG and Alexa 
Fluor 555 donkey anti-goat IgG (Thermo Fisher Scientific), 
then washed 3 times with PBS and mounted using DAPI-
containing mounting medium (Sigma Aldrich). Images were 
acquired using an Axio Imager 2 fluorescence microscope 
(Carl Zeiss MicroImaging GmbH, Germany) equipped 
with excitation and emission filters compatible with the 
fluorophores.
In situ proximity ligation assay
Receptor–receptor interactions were estimated using the 
Duolink II in situ Proximity Ligation Assay (PLA) detec-
tion kit (Sigma Aldrich) according to the manufacturer’s 
protocol. Slides with tissue sections (thickness: 5 µm) were 
fixed in 4% paraformaldehyde in PBS (Sigma Aldrich). and 
incubated overnight at 4 °C in Duolink II Antibody Diluent 
solution with a mixture of primary antibodies: rabbit poly-
clonal anti-mGlu4 receptor antibody (1:100, SAB4501322, 
Sigma Aldrich) and goat polyclonal anti-5-HT1A receptor 
antibody (1:200, ab101914, Abcam) fallowed by incubated 
with PLA probes (Duolink II anti-Goat-MINUS and Duolink 
II anti-Rabbit-PLUS) for 1 h at 37 °C in a humidified cham-
ber.. Then, the ligation reaction was performed at 37 °C for 
30 min in a humidified chamber. Amplification mixture was 
added for 100 min at 37 °C in a darkened humidified cham-
ber. Immunofluorescence staining and positive PLA signals 
were detected using the Axio Imager 2 fluorescence micro-
scope with Zen 2 Pro Software (Carl Zeiss MicroImaging 
GmbH, Germany).
Data analysis
Data obtained from cAMP assay and FRET experiments 
were analyzed with Prism Version 5.04 (GraphPad Software 
Inc.). Each experiment was performed three times (n = 3), 
and each data point was in triplicate. The curves for the 
data shown were fitted to a three-parameter logistic equation, 
allowing for the determination of  IC50 values and Emax. For 
comparison of  IC50 between the curves, t test was applied. 
The ONE way ANOVA and Tukey’s post hoc test were used 
for in vitro receptor interaction assays statistics.
Results
cAMP accumulation assays
In all experiments, cells expressing tagged receptors as for 
FRET measurement were used.
The  IC50 of the inhibition of forskolin-stimulated cAMP 
production by l-glutamate in cells expressing mGlu4 
receptors (T-REx-293-GRM4-SNAP cells) was 15.14 μM 
[± 5.63 μM (SD)] (Fig. 1A). The positive allosteric modula-
tor of mGlu4 receptors VU0155041 (1 µM) shifted the curve 
to the left, decreasing the  IC50 value to 3.74 μM [± 4.03 μM 
(SD)] (t test: p = 0.048; t = 2.837). Average shift of  IC50 
value for PAM was 3.98 [± 1.89 (SD)].
The  IC50 for the inhibition of forskolin-stimulated cAMP 
production by an agonist of 5-HT1A receptors (R)-(+)-8-OH 
DPAT in cells expressing 5-HT1A receptors (T-REx-293-
h5-HT1A-SNAP cells) was 310 nM [± 230 nM (SD)]. The 
effect of the agonist Emax was totally abolished by an antago-
nist of 5-HT1A receptors WAY100135 (Fig. 1b).
Similar procedure was applied in cells expressing both 
receptors: 5-HT1A-HALO and mGlu4R-SNAP (Fig. 2). 
After inducing mGlu4R expression, l-glutamate inhibited 
forskolin-induced cAMP accumulation in a concentration-
dependent manner, with an  IC50 of 5.79 µM [± 3.19 µM 
(SD)], without the induction of receptor expression, 
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L-glutamate was not effective and determination of the 
curve parameters was impossible (Fig. 2a). The 5-HT1A 
receptor agonist action was observed only in cells without 
tetracycline-induced mGlu4 receptor expression. (R)-(+)-
8-OH DPAT without the presence of the mGlu4 recep-
tor (−Tet) displayed an  IC50 of 62 nM [± 45 nM (SD)] 
(Fig. 2b). After the induction of mGlu4 receptor expres-
sion (+Tet), the effect of (R)-(+)-8-OH DPAT was abol-
ished (Fig. 2b).
Addition of sulfasalazine (SSZ) to cell culture medium 
markedly changed 5-HT1A receptor activity in cells cul-
tures coexpressing mGlu4 receptors (+Tet)( Fig. 3). Not 
only it was possible to evaluate the  IC50 for 5-HT1A recep-
tor agonist which was 0.30 µM [± 0.24 µM (SD)] but what 
is important, the  Emax was 2–3 times higher than in cells 
without SSZ (Fig. 3a). Concerning the mGlu4 receptors, 
the  IC50 for l-glutamate, was decreased in presence of SSZ 
to 9.78 µM [± 0.99 µM (SD)] from 16.92 µM [± 3.84 µM 
(SD)] (Fig. 3b) (t test: p = 0.0356; t = 3.119 df = 4).
In vitro receptors interaction assay
At first, the homodimerization of 5-HT1A or mGlu4 recep-
tors fused with SNAP-tag protein and separately expressed 
in the T-REx 293 cell line was analyzed. A homogenous 
time-resolved FRET assay was used to analyze the inter-
action between receptors labeled with Snap-Tb and Snap-
green. For each experiment, a group named “mix cells” 
(1:1) was added, which corresponded to a mixture of cells 
separately labeled with one substrate depending on the 
experimental procedure and mixed immediately before 
FRET measurement.
The 5-HT1A receptor showed a significant increase 
in FRET signal in double-labeled cells compared to the 
buffer alone, nonlabeled cells, single-labeled cells, or cell 
mixture alone (1:1), which indicates homodimerization 
of the 5-HT1A receptor (Fig. 4a). In all experiments, the 
increase varied from 1.6 to 3.3. The ratio of FRET to Snap-
Tb signal (520/490), which corresponded to interactions 
between receptors labeled with both fluorescence probes, 
did not show any changes in the presence of two concen-
trations (1 or 100 μM) of the 5-HT1A receptor agonist, 
(R)-(+)-8-OH DPAT (Fig. 4b).
Fig. 1  a The curve of representative effects of increased concentra-
tions of L-Glu on cAMP accumulation with or without the presence 
of VU0155041, an mGlu4 receptor PAM in cells overexpressing 
human GRM4 fused with SNAP. The results show mean ± SD from 
three replicates. b The 5-HT1A agonist (R)-(+)-8-OH DPAT induced 
inhibition of 5 µM forskolin-stimulated cAMP production in T-REx 
293 cells overexpressing human  5HT1A receptor tagged with Snap 
protein. The effect of the agonist was abolished by the addition of an 
5-HT1A antagonist WAY100135
Fig. 2  Effect of the coexpression of 5-HT1A and mGlu4 in the T-REx 
293 cell line. The expression of mGlu4R was induced by tetracycline 
administration (+ Tet). a Effect of L-glutamate on forskolin-stimu-
lated cAMP accumulation in cells with or without tetracycline induc-
tion. b Effect of (R)-(+)-8-OH DAPT on forskolin-stimulated cAMP 
accumulation in cells with or without tetracycline induction
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The mGlu4 receptor showed significant increase (× 60 
times) in FRET signal in double-labeled cells as compared 
to nonlabeled cells, buffer or cell mixture alone, suggesting 
the close proximity of the mGlu4 monomers that formed 
homodimer in the T-REx 293 cell line (Fig. 4c). The endog-
enous mGlu receptor agonist l-glutamate induced a con-
centration-dependent increase in the HTRF ratio 520/490 
(Fig. 4d).
When the interaction between mGlu4 and 5-HT1A recep-
tors tagged with the Snap-Tb and Halo-Alexa 488 substrates, 
respectively, was analyzed, the FRET signal of the cells 
labeled with both substrates was significantly higher in com-
parison to the single substrate-labeled cells or cell mixtures, 
what indicated that these two receptors form heterodimers 
(Fig. 4e). However, the calculated 520/490 nm ratio in cells 
incubated with (R)-(+)-8-OH DPAT (100 μM) or L-Glu 
(100 μM) did not change (Fig. 4f). These results indicate 
that the proximity of both receptors expressed in the T-REx 
293 cell line was not changed in the presence of agonists.
The influence of positive allosteric modulator (PAM) 
VU0155041 and non-selective antagonist of group II/III 
mGlu receptors LY341495 on FRET signal are presented on 
Fig. 5. PAM enhanced interaction between mGluR4 mono-
mers labeled with donor or acceptor. Shift of  IC50 for PAM 
was 5.11 [± 0.84 (SD)]. An opposite effect was observed 
upon administration of the antagonist of group II/III mGlu 
receptors LY341495, which significantly attenuated the 
FRET signal between the mGluR4 monomers. Shift of IC50 
for NAM was 3.98[± 0.73 (SD)].
In situ mGlu4 and 5‑HT1A receptor expression
The expression levels of mRNAs encoding the mGlu4 recep-
tor (GRM4) and the 5-HT1A receptor (Htr1a) were detected 
using the RNAScope dual fluorescence in situ hybridization 
method which allows for the visualization of a single mole-
cule of mRNA [27]. The expression of the studied transcripts 
was evaluated in MEnt and CA1 (Fig. 6a) according to the 
mouse brain atlas (Paxinos and Watson, 1986). The obtained 
signal (green dots for GRM4 and red dots for Htr1a) indi-
cated that mRNAs encoding of GRM4 and Htr1a receptors 
are co-expressed in the enthorinal cortex (MEnt). The abun-
dance of GRM4 and Htr1a mRNA was also observed in 
some cells in the CA1 field of the hippocampus.
The occurrence of mGlu4-5-HT1A receptor heterore-
ceptor complexes was studied by PLA method in the CA1 
and MEnt. The PLA (red dots), indicating close mGlu4 and 
5-HT1A receptor proximity (< 17 nm) was confirmed in 
both regions of the mouse brain (Fig. 6b).
The colocalization of the proteins of mGlu4 and 5-HT1A 
receptors visualized by immunofluorescence labelling was 
detected in the CA1, as well as MEnt (Fig. 7), again confirm-
ing the proximity of both receptors.
Discussion
In the present work, we decided to investigate the possible 
molecular interaction of the  mGlu4 and 5-HT1A receptors 
in T-REx 293 cells line based on previous result obtained 
in vivo (see “Introduction”).
Receptors functionality was analyzed in the cAMP accu-
mulation assays in the T-REx 293 cell line overexpressing 
or not mGluR4 and 5-HT1A tagged with –SNAP or –HALO, 
respectively. Expression of mRNA was quantified by qRT-
PCR (Fig. S2). Level of mGluR4 mRNA was increased over 
40 times in cells treated with Tet as compared to non-stimu-
lated cells and ratio HTR1A:GRM4 was comparable 1:1.4 in 
the cells expressing both transcripts. As receptor agonist, we 
used l-glutamate an endogenous ligand of all mGlu receptors 
including mGlu4. It is obviously not a selective ligand, how-
ever, in the studied system there are no other mGlu receptors 
that can respond to L-glutamate and downregulate cAMP 
level after forskolin stimulation beside overexpressed mGlu4 
receptors. There were no significant changes in receptor 
activity in the cell lines expressing one of the receptors with-
out tags (Fig. S4A/B). In the cell line with stable expression 
Fig. 3  Effect of sulfasalazine (SSZ) at a concentration of 100 μM on 
receptors activity in cAMP accumulation assay. a Sulfasalazine treat-
ment significantly enhanced 5-HT1A activity in presence of mGlu4 
receptors (filled triangle) in comparison to cells without sulfasalazine 
administration (filed square) where expression of mGluR4 induced by 
tetracycline inhibited the serotonin receptor function. b Sulfasalazine 
treatment shifted the dose–response curve of glutamate to the left
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of the serotonin 5-HT1A receptor, an agonist, (R)-(+)-8-OH 
DPAT, inhibited of cAMP production in a concentration-
dependent manner, with the  IC50 of 0.14 µM (Fig. S4A). 
In the cell line with inducible expression of mGlu4 recep-
tors (Fig. S4B), L-Glu induced a concentration-dependent 
inhibition of forskolin-stimulated cAMP accumulation with 
an  IC50 of 10 µM. These results confirmed that normal bio-
logical activity was preserved despite tag sequence insertion 
into the open reading frame (ORF). However, in the cell 
line coexpressing the 5-HT1A and mGlu4 tagged receptors, 
glutamate induced a concentration-dependent inhibition of 
cAMP accumulation in cells with inducible expression of 
mGlu4R, while the inhibitory effect of (R)-(+)-8-OH-DPAT 
was observed only in cells without tetracycline-induced 
expression of mGlu4 receptors (Fig. 2). This shows that the 
induction of mGlu4 receptors abolished the inhibitory action 
of (R)-(+)-8-OH-DPAT and demonstrates that an inhibitory 
functional interaction between both receptors takes place. 
The mechanism of this interaction at present is difficult to 
explain. The canonical mechanism of action of mGlu4 and 
5-HT1A receptors is via Gi protein activation. If both recep-
tors have different affinities for the Gi protein in the T-REx 
Fig. 4  FRET intensity in 
T-REx 293 overexpressing 
system between the receptors 
labeled with Snap-Tb (donor) 
and Snap-Green (acceptor) 
presented on the surface of the 
cells (a, b 5-HT1A; receptor 
cells, c, d mGlu4 receptor 
cells). The signal was meas-
ured at the specific emission 
of 520 nm for the acceptor and 
at 490 nm for the donor after 
excitation at 340 nm. a and c 
FRET intensity in single- and 
b and d in double-labeled cells. 
The ratio of FRET and Snap-
Tb × 104 in double-labeled cells 
treated with agonist (R)-(+)-
8-OH DPAT (b) or l-glutamate 
(d). e and f Demonstrate the 
interaction between mGlu4 and 
5-HT1A receptors tagged with 
Snap-Tb and Halo-Alexa 488, 
respectively, presented on the 
surface of the T-REx 293 cell 
line. e A significant (p < 0.001) 
increase in FRET fluorescence 
was observed in the double-
labeled cells. f The effect of 
glutamate and/or (R)-(+)-8-OH 
DPAT on the ratio of FRET and 
Snap-Tb/Halo-Alexa 488 × 104. 
ONE-way ANOVA **p < 0.01, 
***p < 0.001
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293 cell line, the competition for the same binding site on 
the Gi protein might favor one receptor that has a better 
molecular fit. Some of the results presented in other papers 
might confirm such a hypothesis [28, 29]. Similar effects 
were observed when 5-HT1A and 5-HT7 receptors were co-
expressed. Functionally, heterodimerization decreased the 
5-HT1A receptor-mediated activation of Gi protein without 
affecting 5-HT7-receptor-mediated signaling [17]. In another 
work, [30] the co-expression of mGlu2 and mGlu4 recep-
tors in HEK-293 cells had a significant inhibitory effect on 
Emax in the cAMP accumulation assay, especially in the pres-
ence of a selective receptor agonist as compared to a single 
receptor-overexpressing cell line. Another premise for cross-
talk between mGlu4 and 5-HT1A receptors in T-REx 293 
cell line comes from the experiment with SSZ added to cul-
ture medium simultaneously with the induction of mGluR4 
expression. As an inhibitor of cysteine-glutamate antiporter 
it decreases the extracellular level of glutamate. One may 
suspect that a certain amount of glutamate could be secreted 
to the culture medium and activate mGluR4 receptor, which 
in turn can dampen the full activity of 5-HT1A receptor. 
Indeed, the addition of SSZ improved activity of both recep-
tors but this effect was more pronounced for 5-HT1A since 
SSZ increased both the efficacy and the affinity of 5-HT1A 
receptor agonist (R)-(+)-8-OH-DPAT. These results confirm 
the interaction and modulation of 5-HT1A activity in T-REx 
293 heterologous system by mGluR4 at least on signaling 
cascade level. Moreover, all cAMP experiments confirm 
the proper expression of the tagged and untagged receptors 
in the cell membrane of T-REx 293cell line and their full 
activity.
To analyze the direct interaction of the mGlu4 and 
5-HT1A receptors, we used the same tagged cell line as for 
Fig. 5  Representative FRET results demonstrating changes in the 
interaction between the hmGlu4 receptor on the surface of T-REx 
293 cells. To label receptors on the cell surface, we used SNA-Tb 
and SNAP-green membrane-impermeable substrates. a The effect 
of L-glutamate alone or in the presence of VU0155041 (10 μM). In 
the presence of VU0155041, the positive allosteric modulator, this 
process was enhanced (t test p < 0.0001 t = 18.0236 df = 4). b The 
effect of L-glutamate alone or in the presence of LY341495 a non-
selective antagonist, which decreased the FRET to SNAP-Tb signal 
ratio. LY341495 in concentration 100 µM exerted strong antagonis-
tic effects, shifting the concentration curve to the left and downwards. 
For L-glutamate  IC50 was 48.18 μM, SD ± 16.15 μM
Fig. 6  a Dual RNAscope for 
Htr1a (red) and GRM4 (green) 
probes in the medial entorhi-
nal cortex (MEnt) and the 
CA1 field of the hippocampus 
(CA1). Nuclei are stained with 
DAPI (blue). b mGlu4/5-HT1A 
receptor heteromerization in 
the mouse brain mGlu4/5-HT1A 
receptor heteromerization was 
visualized by in situ PLA. The 
brain regions for PLA analy-
sis were chosen according to 
Paxinos and Franklin (2001). 
mGlu4/5-HT1A receptor heter-
omers as red dots in MEnt and 
CA1. Nuclei are stained blue 
and scale bars = 20 µm
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cAMP accumulation assay. One of the available methods 
that allow for the analysis of the interactions of two proteins 
is homogenous time-resolved FRET (HTRF). In our experi-
ment, the receptors were tagged with small enzymatic pro-
teins, SNAP or HALO, that selectively recognize and bind 
fluorescent substrates, and can serve as fluorescence donors 
or acceptors for FRET experiments. All fluorescence tags 
used in FRET assay were cell membrane impermeable and 
they bound to receptors located on the cell surface. We used 
SNAP-tag in experiments in which the interaction of homo-
receptors was analyzed as control experiments for positive 
interaction between homomers 5-HT1A or mGluR4.
Overexpression of the serotonin 5-HT1A receptor in the 
heterologous cell system showed a statistically significant 
increase in the FRET signal (Fig. 4a) as compared to the 
controls conditions, which indicates close interaction, 
namely oligomerization or dimerization of 5-HT1AR, and 
remains in agreement with previously published data [31, 
32]. We could not observe any changes in fluorescence sig-
nal after 5-HT1A receptor agonist administration (Fig. 4b), 
while Kobe et al. reported that such agonist decreased FRET 
signal over a few minutes, however, they studied different 
compound we used the selective 5-HT1A R agonist (R)-(+)-
8-OH DPAT because of the possibility of the presence of 
other serotonin receptors on the HEK-293 cell line, such as 
5-HT7 or 5-HT6 [31, 33].
Interesting data were obtained in the cells expressing the 
mGlu4 receptor. We confirmed previous results that indi-
cated mGlu4 receptors can form homodimers or homooli-
gomers [19]. In contrast to the 5-HT1A receptors, the FRET 
signal in the double-stained (SNAP-Tb/ SNAP-green) 
SNAP-mGlu4 receptor cell line was much stronger than 
that of the background and controls (Fig. 4c). In the pres-
ence of increasing concentrations of L-Glutamate, the FRET 
signal was increased Fig. 4d), indicating conformational 
changes in VFT tagged with the SNAP protein, decreasing 
the distance between the two different VFT domains. These 
results are in contrast to most available data concerning 
mGlu receptor interactions. It has been found that following 
agonist administration, the relative movement of the ligand-
binding domain was decreased in mGlu2 tagged receptors 
[34]. Moreover, recent data also showed a dose-dependent 
decrease of inter-subunit FRET following L-Glu adminis-
tration for the mGlu4 receptor [30]. These divergent results 
concerning VFT movements might arise from differences in 
plasmid preparation and final SNAP-tag localization on the 
surface of the cellular membrane. According to the avail-
able literature describing the preparation of the construct 
the mGlu receptor sequence comes after the sequence of the 
N-signaling peptide of the mGlu5 receptor, and SNAP-tag 
[19, 35, 36]. Compared to the construct used in the present 
work, the SNAP-tag sequence is located within the mGlu4 
receptor sequence after the mGluR4 its own signaling pep-
tide. This means that the position of the SNAP-tag differs 
by approximately 30 aa between constructs. Moreover, the 
sequence that we used in the present work is human com-
plementary DNA. The differences between human and rat 
mGlu4 receptor sequences and the different preparation 
of plasmids may contribute to differences in the observed 
movement of extracellular domain that was tagged with 
Fig. 7  mGlu4 and 5-HT1A receptors co-localize in different regions of 
the mouse brain. The sections of the brain labeled with anti-mGlu4 
receptor primary antibody and detected with Alexa488 donkey anti-
rabbit secondary antibody (green) are shown in the first column. 
The sections labeled with anti-5HT1A receptor (5-HT1AR) primary 
antibody and detected with Alexa555 donkey anti-goat secondary 
antibody (red) are shown in the second column. The nuclei labeled 
with DAPI (blue) are shown in the third column. Figure 6 also dem-
onstrated the specificity of antibody anti 5-HT1a and anti-mGluR4 
used for colocalization staining. Both demonstrated localization in 
well known and described region of expression like: CA1 piramidal 
cells layer. In merge arrows indicate some of cells and regions stained 
with DAPI only where antibodies did not bind to antigens. Scale 
bars = 20 µm
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SNAP. Nevertheless, modifications of the N terminus did 
not affect the function of mGlu4 receptors in the present 
work or others [30].
In the present work, we also analyzed the influence of 
the group II/III mGlu receptor antagonist LY341495 [37] 
and a PAM of mGlu4 receptors VU0155041 [38]. Despite 
LY341495 being known as mGlu2/3 receptors antagonist it 
showed a higher potency on mGlu4R than CPPG a selective 
group III antagonist (Fig. S4C). In the presence of L-Glu-
tamate, administration of PAM dose-dependently enhanced 
the intersubunit interaction, while the antagonist resulted in 
the opposite effect, demonstrating that both compounds had 
an influence on the relative movement of the VFT domain 
of the mGlu4 receptor where the SNAP tag was located 
(Fig. 5). According to the current knowledge, modulators 
bind to allosteric sites located in 7TM. In the present study, 
PAM not only changed the activity of the receptor but also 
affected molecular changes in the extracellular part of the 
mGlu4 receptor, moving the two VFT domains closer and, 
therefore, increasing FRET efficiency. Thus, this indicates 
that the extracellular part of the receptor is also affected by 
molecular changes in the transmembrane domain.
The T-REx 293 cell line that overexpressed both receptors 
exhibited a statistically significant increase in FRET signal 
after staining with SNAP and HALO substrates compared to 
control samples (Fig. 4e). This result indicates that the two 
receptors are located in close proximity to one another in 
our experimental heterologous cell system. The FRET signal 
was within the range of 5-HT1A receptor interactions and 
was much weaker than the homo-oligomerization of mGlu4 
receptors. The pair of 5-HT1A and mGlu4 receptors shows a 
large difference in the size of the extracellular domain, which 
might result in a low FRET signal. In other words, the dis-
tance between the donor and acceptor might be much greater 
than the mGlu4-mGlu4 receptor interaction which impairs 
the energy transfer. According to information included in 
the patent by Doumazane et al., the energy transfer between 
donor and acceptor substrates used in HTRF experiments 
appears at a distance of ~ 20–55 Å (US8697380B2, 2014). 
Nevertheless, additional procedures like an expression of 
both receptors in T-REx 293 cell line at a lower level than 
used in present work and disruption of potential oligomers 
by means of TAT-peptides technique are necessary to con-
firm their oligomerizations at least on non-neuronal cells.
To investigate the possibility of 5-HT1A and mGluR4 
interaction in natural biological systems we analyzed the 
expression of mRNA encoding these receptors in the mouse 
brain. In comparison to methods where antibodies are used, 
this approach seems more specific in demonstrating the cells 
and brain regions where such interaction could take place 
due to the appearance of both transcripts. The results clearly 
demonstrated that the medial ethorinal cortex (MEnt) is the 
region where the expression of both receptors is high, which, 
together with the observation of a strong PLA signal, con-
firms the close relative position of both receptors. Also the 
hippocampus (the CA1) represents the region where both 
receptor proteins were found and the PLA approach con-
firmed their close proximity. Regarding the CA1, the levels 
of mRNA transcripts differed slightly from protein expres-
sion, what might result from the different half-lives of the 
same mRNA molecule in various brain structures. As shown 
with the PLA approach, both receptors are sufficiently close 
to each other to interact at the molecular level, i.e., forming 
oligomers or modulating their signaling pathways, in the 
hippocampus. Our investigations did not allow us to dem-
onstrate the exact cell type that co-expressed the receptors 
in the MEnt and CA1. In the hippocampus CA1, the immu-
nofluorescence signal from mGlu4 and 5-HT1A receptors 
was located mainly in the pyramidal and granular cell layers, 
respectively. Additionally, the PLA method confirmed the 
high degree of receptor colocalization in the CA1 field of 
the hippocampus. It is important to mention that immuno-
fluorescence staining gives a linear signal based on protein 
expression. Due to the high level of signal enhancement in 
the PLA, this method provides information about where two 
proteins are located in relation to one another rather than 
about the expression level.
Results obtained in the present work demonstrate cross-
talk between receptors in HEK-293 heterologous expres-
sion system and confirm the close proximity of mGlu4 and 
5-HT1A receptors in the mouse brain slices what has been 
suggested in our previous in vivo study. These preliminary 
findings may represent another signaling route involved in 
the development of psychiatric disorders such as schizophre-
nia or depression as well as provide potential new treatment 
options [39].
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